Cancer Research Consortium of West Michigan
Breast Clinical Trials
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
Provided drugs are underlined
For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079
- Adult
- Pediatric
- Adolescent and Young Adult
(Refer to Clinical Summary for age requirements)
Breast
NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts
A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study
NSABP B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study. Olaparib vs Placebo. Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.
ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1207: Phase III randomized trial. Endocrine Therapy + Everolimus/Placebo. High-risk hormone receptor positive and HER2/NEU negative breast cancer. Staging I-III.
NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
CTSU E2112: Phase III Trial; Endocrine Therapy Plus Entinostat/Placebo; Patients with Hormone Receptor-Positive Advanced Breast Cancer
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
RTOG 1119: Phase II Randomized Study. WBRT +/- Lapatinib in patients with brain metastasis from HER2-Positive breast cancer. Stage IV.
SCRI BRE 203: A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).
ACCRU RU011201I A Randomized Phase III Trial of Eribulin vs Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Not available at Lakeland HealthCare
Staging: 1st or 2nd Line, Locally Recurrent or Metastatic Stage IV or Stage IIIC Not Amenable To Local Therapy, HER2(-). Treatment: Eribulin vs Paclitaxel
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole.
Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo